FR10C0036I2 - - Google Patents

Info

Publication number
FR10C0036I2
FR10C0036I2 FR10C0036C FR10C0036C FR10C0036I2 FR 10C0036 I2 FR10C0036 I2 FR 10C0036I2 FR 10C0036 C FR10C0036 C FR 10C0036C FR 10C0036 C FR10C0036 C FR 10C0036C FR 10C0036 I2 FR10C0036 I2 FR 10C0036I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR10C0036C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18447824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of FR10C0036I1 publication Critical patent/FR10C0036I1/fr
Application granted granted Critical
Publication of FR10C0036I2 publication Critical patent/FR10C0036I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR10C0036C 1992-12-02 2010-07-19 Active FR10C0036I2 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP35619792 1992-12-02

Publications (2)

Publication Number Publication Date
FR10C0036I1 FR10C0036I1 (ar) 2010-08-27
FR10C0036I2 true FR10C0036I2 (ar) 2011-04-29

Family

ID=18447824

Family Applications (1)

Application Number Title Priority Date Filing Date
FR10C0036C Active FR10C0036I2 (ar) 1992-12-02 2010-07-19

Country Status (7)

Country Link
US (1) US5387603A (ar)
EP (1) EP0600675B1 (ar)
JP (1) JP2944402B2 (ar)
KR (1) KR100274329B1 (ar)
CA (1) CA2110454C (ar)
DE (2) DE69319551T2 (ar)
FR (1) FR10C0036I2 (ar)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9095998A (en) * 1997-09-22 1999-04-12 Kissei Pharmaceutical Co. Ltd. Remedies for dysuria resulting from prostatic hypertrophy
DE69916586T2 (de) * 1998-02-27 2004-09-16 Kissei Pharmaceutical Co., Ltd., Matsumoto Indol-derivate und medizinische zusammensetzungen die diese enthalten
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
JP4634560B2 (ja) * 2000-01-14 2011-02-16 キッセイ薬品工業株式会社 光学活性なインドリン誘導体の製造方法およびその製造中間体
US6849655B2 (en) * 2000-05-15 2005-02-01 Kissei Pharmaceutical Co., Ltd. Aqueous liquid formulations
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
JP4921646B2 (ja) * 2001-03-08 2012-04-25 キッセイ薬品工業株式会社 １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法
EP1293198B1 (en) * 2001-09-14 2005-02-09 Schwarz Pharma Ag Device for transdermal administration for the treatment of urinary tract disorders
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
CA2679030A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary track symptoms
ME00076B (me) * 2002-12-16 2011-02-10 Kissei Pharmaceutical Lijek u čvrstom obliku za oralnu primjenu
US20070167511A1 (en) 2004-03-05 2007-07-19 Kissei Pharmaceutical Co,. Ltd. Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder
JP4847333B2 (ja) * 2004-09-06 2011-12-28 キッセイ薬品工業株式会社 排尿障害の予防又は治療薬
ZA200703996B (en) * 2004-10-27 2008-09-25 Kissei Pharmaceutical Indoline compound and process for producing the same
CN101336230B (zh) * 2005-11-24 2011-11-23 橘生药品工业株式会社 用于治疗输尿管结石病的药物
CN101190890B (zh) * 2006-11-30 2011-04-27 江苏豪森药业股份有限公司 5-[(2r)-[2-[2-[2-(2,2,2-三氟乙氧基)苯氧基]乙基]氨基]丙基]-2-甲氧基苯磺酰胺
US20100076010A1 (en) * 2007-02-26 2010-03-25 Concert Pharmaceuticals, Inc. Alpha 1a-adrenoceptor antagonists
US8013007B2 (en) * 2007-02-26 2011-09-06 Concert Pharmaceuticals, Inc. Alpha 1A-adrenoceptor antagonists
WO2008106536A1 (en) * 2007-02-28 2008-09-04 Kissei Pharmaceuticals Co., Ltd. Use of silodosin in a once daily administration for treating benign prostatic hyperplasia
CN101993405B (zh) * 2009-08-27 2014-01-15 浙江华海药业股份有限公司 吲哚啉衍生物、及其制备方法和用途
CN101993407B (zh) * 2009-08-27 2014-01-29 浙江华海药业股份有限公司 用于制备西洛多辛的吲哚啉化合物及其制备方法
JP5661773B2 (ja) 2009-09-12 2015-01-28 サンド・アクチエンゲゼルシヤフト インドリン誘導体の調製方法およびこれらの中間体
CN101768056B (zh) * 2010-01-19 2013-10-16 扬子江药业集团有限公司 一种取代的苯基甲基醚的制备方法
WO2011101864A1 (en) 2010-02-17 2011-08-25 Panacea Biotec Ltd Novel process for the synthesis of phenoxyethyl derivatives
WO2011124704A1 (en) 2010-04-09 2011-10-13 Ratiopharm Gmbh Process for preparing an intermediate for silodosin
WO2012000926A1 (de) 2010-06-28 2012-01-05 Ratiopharm Gmbh Silodosin-cyclodextrin einschlussverbindungen
CN102311319A (zh) * 2010-07-05 2012-01-11 浙江华海药业股份有限公司 一种制备2-(2,2,2-三氟乙基)苯甲醚的方法
WO2012010669A2 (de) 2010-07-23 2012-01-26 Ratiopharm Gmbh Arzneimittel zur oralen verabreichung umfassend ein gemisch aus silodosin und einem basischen copolymer
WO2012014186A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Process for the preparation of silodosin and its novel intermediates
WO2012062229A1 (en) 2010-11-12 2012-05-18 Zentiva, K.S. A method of manufacturing (-)-l-(3-hydroxypropyl)-5-[(2r)-2-({2,2,2-trifluoroethoxy)- phenoxyethyl}amino)propyl]-2,3-dihydro-lh-indole-7-carboxamide
WO2012077138A1 (en) 2010-12-09 2012-06-14 Panacea Biotec Limited Methods of crystallizing (r) -1- (3 -hydroxypropyl) -5- [2- [2- [2- ( 2, 2, 2 - trifluoroethoxy) phenoxy] ethylamino] propyl] indoline-7 -carboxamide
CN102050709B (zh) * 2010-12-22 2014-09-10 合肥信风科技开发有限公司 2-[2-(2，2，2-三氟乙氧基)苯氧基]乙醇的制备方法
US20120184591A1 (en) 2011-01-13 2012-07-19 Watson Pharmaceuticals, Inc. Methods for treating prostatitis
CN102643221B (zh) 2011-02-22 2015-02-11 浙江九洲药业股份有限公司 西洛多辛中间体及其制备方法
WO2012131710A2 (en) 2011-03-30 2012-10-04 Panacea Biotec Ltd Novel process for the synthesis of indoline derivatives
WO2012147107A2 (en) * 2011-04-29 2012-11-01 Msn Laboratories Limited Novel & improved processes for the preparation of indoline derivatives and its pharmaceutical composition
CN102285872A (zh) * 2011-06-17 2011-12-21 连云港万科生物科技有限公司 2-[2,2,2-（三氟乙氧基）-苯氧]乙醇的制备方法
CN102382029B (zh) * 2011-07-26 2016-06-29 浙江华海药业股份有限公司 一种西洛多辛中间体成盐制备方法
CN102283816B (zh) * 2011-08-05 2013-09-11 北京海步国际医药科技发展有限公司 西洛多辛缓释片剂及其制备方法
WO2013061338A1 (en) 2011-08-24 2013-05-02 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
WO2013072935A2 (en) 2011-10-10 2013-05-23 Cadila Healthcare Limited Process for the preparation of silodosin
CN104302621A (zh) 2011-10-21 2015-01-21 桑多斯股份公司 制备西洛多辛的方法
CN102690223A (zh) * 2012-05-24 2012-09-26 临海天宇药业有限公司 1-乙酰基-7-氰基-5-（2-氨基丙基）吲哚啉的制备方法
CN102675182B (zh) * 2012-05-24 2014-03-26 临海天宇药业有限公司 1-(3-苯甲酰氧基丙基)-5-(2-羰基丙基)-7-腈基吲哚啉的制备方法
JP2015533501A (ja) * 2012-10-18 2015-11-26 サンド・アクチエンゲゼルシヤフト インドリン誘導体の調製方法
CN103848772A (zh) * 2012-11-30 2014-06-11 苏州四同医药科技有限公司 一种西罗多辛重要中间体的制备方法
US20160045446A1 (en) 2013-03-26 2016-02-18 Kissei Pharmaceutical Co., Ltd. Oral administration preparation with masked bitterness of silodosin
CN105102429A (zh) * 2013-04-09 2015-11-25 曼康德研究中心 N-卤代烷基吲哚啉中间体，其制备方法和在赛洛多辛及其衍生物的制备中的用途
CN104140389A (zh) * 2013-05-06 2014-11-12 昆明积大制药股份有限公司 一种赛洛多辛及其中间体的制备方法
CN104326963A (zh) * 2013-07-22 2015-02-04 中国科学院上海药物研究所 一类二氢吲哚类化合物、其制备方法、药物组合物及应用
CN104744336B (zh) * 2013-12-26 2017-07-14 安徽省庆云医药股份有限公司 一种西洛多辛中间体及其制备方法，以及用该中间体制备西洛多辛的方法
CN104974072B (zh) * 2014-04-10 2017-11-03 江苏和成新材料有限公司 一种制备西洛多辛中间体的方法
KR101725393B1 (ko) * 2014-07-24 2017-04-27 주식회사 경보제약 실로도신의 제조 방법 및 신규 중간체
WO2016042441A1 (en) 2014-09-18 2016-03-24 Mankind Research Centre A novel process for the preparation of considerably pure silodosin
KR101673160B1 (ko) 2014-10-24 2016-11-07 보령제약 주식회사 실로도신 γ 결정형의 제조방법
JP2016088847A (ja) * 2014-10-30 2016-05-23 株式会社トクヤマ （‐）‐１‐（３‐ヒドロキシプロピル）‐５‐［［（２ｒ）‐２‐（｛２‐［２‐（２，２，２‐トリフルオロエトキシ）フェノキシ］エチル｝アミノ）プロピル］‐２，３‐ジヒドロ‐１ｈ‐インドール‐７‐カルボキサミド］）の製造方法
RU2750898C2 (ru) 2015-09-23 2021-07-05 Биокон Лимитед Кристаллические формы промежуточного соединения позаконазола и способ получения аморфного позаконазола
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
WO2018100565A1 (en) * 2016-11-30 2018-06-07 Granules India Limited Process for the preparation of indoline compound
CN107056675B (zh) 2017-05-10 2019-09-03 浙江天宇药业股份有限公司 一种西洛多辛及其中间体的合成方法
KR102163068B1 (ko) * 2018-07-04 2020-10-07 주식회사 가피바이오 실로도신 합성용 중간체의 제조 방법 및 이를 이용한 실로도신의 제조 방법
CN109516933B (zh) * 2018-10-29 2021-03-02 安徽省庆云医药股份有限公司 一种西洛多辛中间体的制备方法
EP3892615A1 (en) 2020-04-09 2021-10-13 Minakem Process for the preparation of silodosin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA77657A (en) * 1902-09-11 1902-10-07 Adam A. Welsh Cable grip
US4638070A (en) * 1978-12-21 1987-01-20 Continental Pharma Heterocyclic amino-alcohol derivatives
FR2512817A1 (fr) * 1981-09-17 1983-03-18 Roussel Uclaf Nouveaux derives de l'aminomethyl 1h-indole-4-methanol et leurs sels, leur procede de preparation, leur application a titre de medicaments, les compositions les renfermant et leurs intermediaires de preparation
US4521606A (en) * 1983-06-30 1985-06-04 American Home Products Corp. 5-Indolyl substituted aminoethanols
US4971990A (en) * 1988-02-19 1990-11-20 Hokuriku Pharmaceutical Co., Ltd. Phenoxyethylamine derivatives, for preparing the same and composition for exhibiting excellent α1 -blocking activity containing the same

Also Published As

Publication number Publication date
DE69319551D1 (de) 1998-08-13
FR10C0036I1 (ar) 2010-08-27
EP0600675B1 (en) 1998-07-08
EP0600675A1 (en) 1994-06-08
KR940014328A (ko) 1994-07-18
JP2944402B2 (ja) 1999-09-06
CA2110454C (en) 2005-10-25
CA2110454A1 (en) 1994-06-03
DE122010000031I1 (de) 2010-10-21
US5387603A (en) 1995-02-07
DE69319551T2 (de) 1998-10-29
KR100274329B1 (ko) 2001-02-01
JPH06220015A (ja) 1994-08-09

Similar Documents

Publication Publication Date Title
FR10C0036I2 (ar)
DK0574087T3 (ar)
BR9207065A (ar)
DK0581129T3 (ar)
DK0576346T3 (ar)
DK0574276T3 (ar)
TW241388B (ar)
TW242582B (ar)
DK0571172T3 (ar)
TW223140B (ar)
DK0559942T3 (ar)
IN187353B (ar)
IN183023B (ar)
IN181431B (ar)
IN177850B (ar)
BR9304980A (ar)
ECSDI920048S (ar)
AU2098792A (ar)
AU1019892A (ar)
CN3011935S (ar)
AU1045392A (ar)
AU1047592A (ar)
EP0573087A3 (ar)
EP0576948A3 (ar)
EP0597621A3 (ar)